Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics

Eligibility Criteria

• * Ability of participant to understand the requirements of the study, provide written informed consent, and agree to abide by the study requirements
• * Agree to use contraception from time of screening until 14 days after dosing (Day 14) if female is of childbearing potential or male is with female partner of childbearing potential.
• * In good general health based on medical history, physical examination (PE), and screening evaluations.
• * Negative urine or blood screen for drugs of abuse (except if participant provides prescription justifying use prior to urine screen).
• * Body weight ≥ 50 kilogram (kg) and ≤ 110 kg. If body weight is over 110 kg, then body mass index (BMI) will be considered and must be ≤ 40 kg/m\^2.
• * Inability or unwillingness of a participant to give written informed consent or comply with study protocol.
• * Any hematology, chemistry, coagulation, or urinalysis value on screening labs defined in the United States Food and Drug Administration (FDA) Guidance for Industry Toxicity Grading Scale as Grade 1 or higher.
• * Any clinically significant electrocardiogram (ECG) abnormality
• * Pregnant or breastfeeding
• * Active substance abuse or history of any medical or psychiatric condition that would jeopardize the participant's safety or the participant's ability to comply with the protocol.
• * Received an organ transplant (solid or bone marrow).
• * Received a blood transfusion within 3 months of dosing.
• * Difficulty swallowing tablets or capsules.
• * Febrile illness or significant infection within 7 days of dosing.
• * Symptoms of hypotension (lightheadedness, syncope, balance disturbances, or extreme fatigue) within 48 hours of dosing.
• * Hepatitis B virus surface antigen (HBsAg) positive or serologic (antibody positive) evidence of infection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV).
• * Tested positive for SARS-CoV-2 (COVID-19) within 21 days of dosing.
• * Chelation therapy (e.g., ethylenediaminetetraacetic acid \[EDTA\], diethylenetriamine pentaacetate \[DTPA\]) in the past year.
• * Use of laxatives, antibiotics, and/or antacids within 7 days of dosing.
• * Use of investigational drugs within 60 days of dosing or 5 half-lives, whichever is longer.
• * Received a vaccination within 30 days of dosing.
• * Potential allergic reaction to product (oleic acid or HOPO 14-1 product).
• * Past or current medical problems or findings from physical examination (PE) or laboratory testing